Nab-Paclitaxel/Carboplatin Induction in Squamous NSCLC: Longitudinal Quality of Life While on Chemotherapy

Lung Cancer: Targets and Therapy - New Zealand
doi 10.2147/lctt.s138570
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Informa UK Limited

Related search

216PD: Nab-Paclitaxel + Carboplatin (Nab-P/C) in Advanced Non-Small Cell Lung Cancer (NSCLC): Outcomes in Elderly Patients (Pts) With Squamous (SCC) Histology

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

P1.16-21 Phase I / II Study of Carboplatin, Nab-Paclitaxel, and Concurrent Radiotherapy for Patients With Locally Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-93 Quality of Life in Patients With Advanced NSCLC Treated in Second- Or Third-Line With Nab-Paclitaxel + Durvalumab: ABOUND.2L+

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

JCSE01.17 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-48 Nab-Paclitaxel Plus Gemcitabine in Advanced NSCLC After Platinum-Based Chemotherapy: Final Results and Caveolin-1 Expression

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.16-08 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Paclitaxel-Carboplatin Chemotherapy Induced Hematologic Toxicities Among Epithelial Ovarian Cancer Patients

Universa Medicina
2016English

Quality-Adjusted Survival With Nab -Paclitaxel vs Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis

Clinical Breast Cancer
Cancer ResearchOncology
2018English

Nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

Frontiers in Oncology
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy